Date of report 23 Dec 2020
Reported case interaction between
Cobicistat and RIFABUTIN
Cobicistat and RIFABUTIN
Drugs suspected to be involved in the DDI
Complete list of drugs taken by the patient
rifabutin
Clinical case description
A 63-year-old HIV-infected female with a history of latent TB, cirrhosis secodary to non-alcoholic steatohepatitis. The patient has been treated with rifabutin 300 mg daily for a 4 month treatment course 9 months prior. Due to a communication error, the patient was restarted on rifabutin 300 mg daily for 3 months while on treatment with elvitegravir/cobicistat, emtricitabine and tenofovir alafenamide. The patient developed a bilateral panuveitis likely due to the inhibitory effect of cobicistat on rifabutin metabolism leading to high concentrations of rifabutin. Rifabutin-associated uveitis has been recognized as a dosage-dependent side effect. This report was published by Toomey C et al. Case rep Ophthalmol 2020.
Clinical Outcome
Drug Interaction Probability Scale (DIPS)
Editorial Comment
Coadministration is not recommended as it may significantly decrease elvitegravir/cobicistat plasma concentrations, which may result in loss of therapeutic effect and development of resistance. Coadministration of elvitegravir/cobicistat (150 mg/150 mg once daily) and rifabutin (300 mg once daily alone or 150 mg every other day with elvitegravir/cobicistat) decreased elvitegravir Cmin by 67%. Rifabutin exposure was similar to values obtained alone, but 25-O-desacetylrifabutin exposures were 4.8 to 6.3 fold higher. The European SPC suggests that if the combination is needed, to use rifabutin 150 mg 3 times per week on set days (e.g. Monday-Wednesday-Friday) with increased monitoring for rifabutin associated adverse reactions including neutropenia and uveitis due to increased desacetyl rifabutin exposure.
University of Liverpool Recommendation
Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration